Bharath Kumar

Bharath Kumar

Biogen Inc - / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4970879
person_outline Bharath Kumar's MOST POPULAR ARTICLES
1-) Two randomized phase 3 studies of aducanumab in early Alzheimer’s diseaseS Budd Haeberlein, PS Aisen, F Barkhof, S Chalkias, T Chen, S Cohen, ...The Journal of Prevention of Alzheimer\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s Disease 9 (2), 197-210, 20222072022
2-) Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trialJ Elkins, R Veltkamp, J Montaner, SC Johnston, AB Singhal, K Becker, ...The Lancet Neurology 16 (3), 217-226, 20171772017
3-) Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trialAL Boxer, I Qureshi, M Ahlijanian, M Grundman, LI Golbe, I Litvan, ...The Lancet Neurology 18 (6), 549-558, 20191112019
4-) EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s diseaseSB Haeberlein, C Von Hehn, Y Tian, S Chalkias, KK Muralidharan, ...San Diego: 12th Clinical Trials on Alzheimer\'s Disease, 1-25, 2019792019
5-) Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsT Plavina, KK Muralidharan, G Kuesters, D Mikol, K Evans, ...Neurology, 10.1212/WNL. 0000000000004485, 2017772017